BX-004 is under clinical development by BiomX and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BX-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BX-004 is under development for the treatment of cystic fibrosis and resistant pseudomonas aeruginosa infections. It is administered as inhalational formulation. The drug candidate comprises of cocktail of natural phages developed based on BOLT (Bacteriophage Lead to Treatment) platform.
BiomX is a microbiome company that developing natural and engineered phage cocktails targeting harmful bacteria in chronic diseases and conditions such as acne, inflammatory bowel disease (IBD), liver disease. The company’s lead product candidate includes BX003to treat primary sclerosing cholangitis (PSC). BiomX CRC program helps in recognizing and validating associations of specific strains of bacteria. The company BX005 is topical phage product candidate which targeting Staphylococcus aureus. It works in collaboration with Massachusetts Institute of Technology, Janssen Pharmaceuticals, Takeda Pharmaceutical Co Ltd, JSR Corporation and Weizmann Institute of Science. BiomX is headquartered in Ness Ziona, Israel.
For a complete picture of BX-004’s drug-specific PTSR and LoA scores, buy the report here.